Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

Luisa L. Villa, Kevin A. Ault, Anna R. Giuliano, Ronaldo L R Costa, Carlos A. Petta, Rosires P. Andrade, Darron Brown, Alex Ferenczy, Diane M. Harper, Laura A. Koutsky, Robert J. Kurman, Matti Lehtinen, Christian Malm, Sven Eric Olsson, Brigitte M. Ronnett, Finn Egil Skjeldestad, Margareta Steinwall, Mark H. Stoler, Cosette M. Wheeler, Frank J. Taddeo & 11 others Jimmy Yu, Lisa Lupinacci, Radha Railkar, Rocio Marchese, Mark T. Esser, Janine Bryan, Kathrin U. Jansen, Heather L. Sings, Gretchen M. Tamms, Alfred J. Saah, Eliav Barr

Research output: Contribution to journalArticle

297 Citations (Scopus)

Abstract

Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naïve and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were ∼12- to 26-fold higher than those observed in baseline-naïve women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported.

Original languageEnglish
Pages (from-to)5571-5583
Number of pages13
JournalVaccine
Volume24
Issue number27-28
DOIs
StatePublished - Jul 7 2006

Fingerprint

Human papillomavirus 6
Papillomaviridae
Vaccines
vaccines
Virus-Like Particle Vaccines
Human papillomavirus 11
Condylomata Acuminata
Papillomavirus Infections
virus-like particle vaccines
Uterine Cervical Neoplasms
warts
uterine cervical neoplasms
Placebos
genitalia
placebos
Safety
Antibodies
immune response
antibodies
infection

Keywords

  • Human papillomavirus
  • Immunogenicity
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Villa, L. L., Ault, K. A., Giuliano, A. R., Costa, R. L. R., Petta, C. A., Andrade, R. P., ... Barr, E. (2006). Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine, 24(27-28), 5571-5583. https://doi.org/10.1016/j.vaccine.2006.04.068

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. / Villa, Luisa L.; Ault, Kevin A.; Giuliano, Anna R.; Costa, Ronaldo L R; Petta, Carlos A.; Andrade, Rosires P.; Brown, Darron; Ferenczy, Alex; Harper, Diane M.; Koutsky, Laura A.; Kurman, Robert J.; Lehtinen, Matti; Malm, Christian; Olsson, Sven Eric; Ronnett, Brigitte M.; Skjeldestad, Finn Egil; Steinwall, Margareta; Stoler, Mark H.; Wheeler, Cosette M.; Taddeo, Frank J.; Yu, Jimmy; Lupinacci, Lisa; Railkar, Radha; Marchese, Rocio; Esser, Mark T.; Bryan, Janine; Jansen, Kathrin U.; Sings, Heather L.; Tamms, Gretchen M.; Saah, Alfred J.; Barr, Eliav.

In: Vaccine, Vol. 24, No. 27-28, 07.07.2006, p. 5571-5583.

Research output: Contribution to journalArticle

Villa, LL, Ault, KA, Giuliano, AR, Costa, RLR, Petta, CA, Andrade, RP, Brown, D, Ferenczy, A, Harper, DM, Koutsky, LA, Kurman, RJ, Lehtinen, M, Malm, C, Olsson, SE, Ronnett, BM, Skjeldestad, FE, Steinwall, M, Stoler, MH, Wheeler, CM, Taddeo, FJ, Yu, J, Lupinacci, L, Railkar, R, Marchese, R, Esser, MT, Bryan, J, Jansen, KU, Sings, HL, Tamms, GM, Saah, AJ & Barr, E 2006, 'Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18', Vaccine, vol. 24, no. 27-28, pp. 5571-5583. https://doi.org/10.1016/j.vaccine.2006.04.068
Villa, Luisa L. ; Ault, Kevin A. ; Giuliano, Anna R. ; Costa, Ronaldo L R ; Petta, Carlos A. ; Andrade, Rosires P. ; Brown, Darron ; Ferenczy, Alex ; Harper, Diane M. ; Koutsky, Laura A. ; Kurman, Robert J. ; Lehtinen, Matti ; Malm, Christian ; Olsson, Sven Eric ; Ronnett, Brigitte M. ; Skjeldestad, Finn Egil ; Steinwall, Margareta ; Stoler, Mark H. ; Wheeler, Cosette M. ; Taddeo, Frank J. ; Yu, Jimmy ; Lupinacci, Lisa ; Railkar, Radha ; Marchese, Rocio ; Esser, Mark T. ; Bryan, Janine ; Jansen, Kathrin U. ; Sings, Heather L. ; Tamms, Gretchen M. ; Saah, Alfred J. ; Barr, Eliav. / Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. In: Vaccine. 2006 ; Vol. 24, No. 27-28. pp. 5571-5583.
@article{67b29701234b4e0c8b12b6c0be49094c,
title = "Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18",
abstract = "Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-na{\"i}ve and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were ∼12- to 26-fold higher than those observed in baseline-na{\"i}ve women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported.",
keywords = "Human papillomavirus, Immunogenicity, Vaccine",
author = "Villa, {Luisa L.} and Ault, {Kevin A.} and Giuliano, {Anna R.} and Costa, {Ronaldo L R} and Petta, {Carlos A.} and Andrade, {Rosires P.} and Darron Brown and Alex Ferenczy and Harper, {Diane M.} and Koutsky, {Laura A.} and Kurman, {Robert J.} and Matti Lehtinen and Christian Malm and Olsson, {Sven Eric} and Ronnett, {Brigitte M.} and Skjeldestad, {Finn Egil} and Margareta Steinwall and Stoler, {Mark H.} and Wheeler, {Cosette M.} and Taddeo, {Frank J.} and Jimmy Yu and Lisa Lupinacci and Radha Railkar and Rocio Marchese and Esser, {Mark T.} and Janine Bryan and Jansen, {Kathrin U.} and Sings, {Heather L.} and Tamms, {Gretchen M.} and Saah, {Alfred J.} and Eliav Barr",
year = "2006",
month = "7",
day = "7",
doi = "10.1016/j.vaccine.2006.04.068",
language = "English",
volume = "24",
pages = "5571--5583",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "27-28",

}

TY - JOUR

T1 - Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

AU - Villa, Luisa L.

AU - Ault, Kevin A.

AU - Giuliano, Anna R.

AU - Costa, Ronaldo L R

AU - Petta, Carlos A.

AU - Andrade, Rosires P.

AU - Brown, Darron

AU - Ferenczy, Alex

AU - Harper, Diane M.

AU - Koutsky, Laura A.

AU - Kurman, Robert J.

AU - Lehtinen, Matti

AU - Malm, Christian

AU - Olsson, Sven Eric

AU - Ronnett, Brigitte M.

AU - Skjeldestad, Finn Egil

AU - Steinwall, Margareta

AU - Stoler, Mark H.

AU - Wheeler, Cosette M.

AU - Taddeo, Frank J.

AU - Yu, Jimmy

AU - Lupinacci, Lisa

AU - Railkar, Radha

AU - Marchese, Rocio

AU - Esser, Mark T.

AU - Bryan, Janine

AU - Jansen, Kathrin U.

AU - Sings, Heather L.

AU - Tamms, Gretchen M.

AU - Saah, Alfred J.

AU - Barr, Eliav

PY - 2006/7/7

Y1 - 2006/7/7

N2 - Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naïve and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were ∼12- to 26-fold higher than those observed in baseline-naïve women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported.

AB - Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naïve and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were ∼12- to 26-fold higher than those observed in baseline-naïve women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported.

KW - Human papillomavirus

KW - Immunogenicity

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=33746839247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746839247&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.04.068

DO - 10.1016/j.vaccine.2006.04.068

M3 - Article

VL - 24

SP - 5571

EP - 5583

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 27-28

ER -